Literature DB >> 2155700

Silent cirrhosis in patients with hepatocellular carcinoma. Implications for screening in high-incidence and low-incidence areas.

S N Zaman1, P J Johnson, R Williams.   

Abstract

We assessed the frequency of silent (i.e., clinically asymptomatic) cirrhosis among 305 patients with hepatocellular carcinoma (HCC) and cirrhosis in relation to the patients' country of birth, the cause of the cirrhosis, clinical features, and hepatitis B surface antigen (HBsAg) status. Overall, 56% of the patients had silent cirrhosis, but this occurred significantly more frequently among those born in areas of the world where HCC is common (64% compared with 36%), those who were HBsAg-seropositive (75% compared with 25%), and those who had cryptogenic cirrhosis (71% compared with 29%). Previously recognized ("known") cirrhosis was more common among those from low-incidence areas (52% compared with 36%) and the cause of the cirrhosis was more often alcoholic (44% compared with 10%). The clinical features at the time of presentation with HCC did not differ between the two groups. During the 10-year period of the study (1978 to 1988), 448 patients with HCC were seen (including those without cirrhosis and those in whom the presence or absence of cirrhosis could not be determined). Overall, therefore, cirrhosis was recognized before presentation with tumor in only 30% of the patients. The screening of cirrhotic patients can only have a limited impact on the early detection of HCC.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155700     DOI: 10.1002/1097-0142(19900401)65:7<1607::aid-cncr2820650726>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  No direct role for Epstein-Barr virus in American hepatocellular carcinoma.

Authors:  P G Chu; Y Y Chen; W Chen; L M Weiss
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

2.  Hepatocellular carcinoma screening in a hepatitis B virus-infected Korean population.

Authors:  Seung Ha Park; Nae Yun Heo; Jong Ha Park; Tae Oh Kim; Sung Yeun Yang; Hyun Kuk Kim; Young Soo Moon; Chang Hoon Kim; Ki Tae Suk; Dong Joon Kim; Heon Young Lee
Journal:  Dig Dis Sci       Date:  2012-06-23       Impact factor: 3.199

3.  Efficacy of ultrasonography and alpha-fetoprotein on early detection of hepatocellular carcinoma.

Authors:  Fen-Yu Ren; Xi-Xu Piao; Ai-Lian Jin
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

Review 4.  Hepatocellular carcinoma. A worldwide problem and the major risk factors.

Authors:  R G Simonetti; C Cammà; F Fiorello; F Politi; G D'Amico; L Pagliaro
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

Review 5.  Advances in neoplastic disease of the liver and biliary tract.

Authors:  P J Johnson; M L Wilkinson; J Karani
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

6.  Diabetes: one of few remarkable differences in clinicopathologic features between cirrhotic and noncirrhotic Swedes with hepatocellular carcinoma.

Authors:  Jerzy Kaczynski; Göran Hansson; Sven Wallerstedt
Journal:  Dig Dis Sci       Date:  2006-04       Impact factor: 3.199

7.  Helicobacter infection in patients with HCV-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma.

Authors:  Maria P Dore; Giuseppe Realdi; Daniela Mura; David Y Graham; Antonia R Sepulveda
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

8.  Early induction of TGF-beta1 through a fasting-re-feeding regimen promotes liver carcinogenesis by a sub-initiating dose of diethylnitrosamine.

Authors:  L Tessitore; E Bollito
Journal:  Cell Prolif       Date:  2006-04       Impact factor: 6.831

9.  Settling the "score" with liver cancer.

Authors:  Christopher Koh; T Jake Liang
Journal:  J Hepatol       Date:  2008-10-29       Impact factor: 25.083

10.  Strategies for prediction and mitigation of radiation-induced liver toxicity.

Authors:  Diego A S Toesca; Bulat Ibragimov; Amanda J Koong; Lei Xing; Albert C Koong; Daniel T Chang
Journal:  J Radiat Res       Date:  2018-03-01       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.